Thomas VV, Kumar SE, Alexander V, Nadaraj A, Vijayalekshmi B, Prabhu S, Kumar S, Murugabharathy K, Thomas SM, Hansdak S, Carey R, Iyyadurai R, Pichamuthu K, Abhilash KPP, Varghese GM, Nair S, Goel A, Jeyaseelan L, Zachariah U, Zachariah A, Eapen CE. Plasma Von Willebrand Factor Levels Predict Survival in COVID-19 Patients Across the Entire Spectrum of Disease Severity. Indian J Hematol Blood Transfus. 2021 Jun 20:1-8. doi: 10.1007/s12288-021-01459-0. Epub ahead of print. PMID: 34177141; PMCID: PMC8214842.

Santhosh E. Kumar, Ashish Goel, Uday Zachariah, Sukesh C. Nair, Vinoi G. David, Santosh Varughese, Prashanth B. Gandhi, Amit Barpha, Anand Sharma, Balakrishnan Vijayalekshmi, Kunissery A. Balasubramanian, Elwyn Elias, Chundamannil Eapen Eapen, Low Volume Plasma Exchange and Low Dose Steroid Improve Survival in Patients With Alcohol-Related Acute on Chronic Liver Failure and Severe Alcoholic Hepatitis – Preliminary Experience, Journal of Clinical and Experimental Hepatology, 2021, ISSN 0973-6883, https://doi.org/10.1016/j.jceh.2021.07.010. (https://www.sciencedirect.com/science/article/pii/S0973688321001778) Abstract: Background Alcohol-related acute on chronic liver failure (A-ACLF) patients have high short-term mortality and are poor candidates for steroid therapy. Plasma exchange (PLEX) improves survival in ACLF patients. We analyzed our experience with low volume PLEX (50% of plasma volume exchanged per session) and low dose steroids to treat A-ACLF patients. Methods We retrospectively compared the efficacy of low volume PLEX and low-dose steroids with standard medical treatment (SMT) in A-ACLF patients treated at our center between November 2017 to June 2019. The primary study outcome was one-year survival. Results Twenty-one A-ACLF patients in PLEX group [age 40 (29–56) years, median (range); MELD score 31 (29–46)] and 29 A-ACLF patients in SMT group [age 41.5 (28–63) years, MELD score 37 (21–48)] were studied. All 50 study patients had severe alcoholic hepatitis [mDF 84.7 (50–389)]. PLEX group patients had 3 (1–7) PLEX sessions with 1.5 (1.4–1.6) liters of plasma exchanged per session and oral Prednisolone 20 mg daily, tapered over 1 month. Kaplan Meier analysis showed better survival over 1 year in the PLEX group compared to the SMT group (P = 0.03). There was renal dysfunction in 10 patients in the PLEX group, which normalized in six patients after PLEX. Conclusion

Kumar SE, Jaleel R, Varghese T, Praharaj I, Benny S, Chowdhury SD, Thomas R, Simon E, Joseph AJ, Dutta AK. Fecal calgranulin as a potential screening tool to differentiate inflammatory bowel disease from irritable bowel syndrome. Indian J Gastroenterol. 2024 Jan 23. doi: 10.1007/s12664-024-01525-1. Epub ahead of print. PMID: 38261246.

Singh KA, Anandan S, Sharma A, Kumar SE, Solaimalai D, Veeraraghavan B, Goel A, Eapen CE, Zachariah UG. High Mortality With Non-O1/Non-O139 Vibrio cholera Bacteraemia in Patients With Cirrhosis. J Clin Exp Hepatol. 2024 May-Jun;14(3):101346. doi: 10.1016/j.jceh.2024.101346. Epub 2024 Jan 17. PMID: 38371607; PMCID: PMC10869911.

Choudhury A, Kulkarni AV, Arora V, Soin AS, Dokmeci AK, Chowdhury A, Koshy A, Duseja A, Kumar A, Mishra AK, Patwa AK, Sood A, Roy A, Shukla A, Chan A, Krag A, Mukund A, Mandot A, Goel A, Butt AS, Sahney A, Shrestha A, Cárdenas A, Di Giorgio A, Arora A, Anand AC, Dhawan A, Jindal A, Saraya A, Srivastava A, Kumar A, Kaewdech A, Pande A, Rastogi A, Valsan A, Goel A, Kumar A, Singal AK, Tanaka A, Coilly A, Singh A, Meena BL, Jagadisan B, Sharma BC, Lal BB, Eapen CE, Yaghi C, Kedarisetty CK, Kim CW, Panackel C, Yu C, Kalal CR, Bihari C, Huang CH, Vasishtha C, Jansen C, Strassburg C, Lin CY, Karvellas CJ, Lesmana CRA, Philips CA, Shawcross D, Kapoor D, Agrawal D, Payawal DA, Praharaj DL, Jothimani D, Song DS, Kim DJ, Kim DS, Zhongping D, Karim F, Durand F, Shiha GE, D'Amico G, Lau GK, Pati GK, Narro GEC, Lee GH, Adali G, Dhakal GP, Szabo G, Lin HC, Li H, Nair HK, Devarbhavi H, Tevethia H, Ghazinian H, Ilango H, Yu HL, Hasan I, Fernandez J, George J, Behari J, Fung J, Bajaj J, Benjamin J, Lai JC, Jia J, Hu JH, Chen JJ, Hou JL, Yang JM, Chang J, Trebicka J, Kalf JC, Sollano JD, Varghese J, Arab JP, Li J, Reddy KR, Raja K, Panda K, Kajal K, Kumar K, Madan K, Kalista KF, Thanapirom K, Win KM, Suk KT, Devadas K, Lesmana LA, Kamani L, Premkumar M, Niriella MA, Al Mahtab M, Yuen MF, Sayed MH, Alla M, Wadhawan M, Sharma MK, Sahu M, Prasad M, Muthiah MD, Schulz M, Bajpai M, Reddy MS, Praktiknjo M, Yu ML, Prasad M, Sharma M, Elbasiony M, Eslam M, Azam MG, Rela M, Desai MS, Vij M, Mahmud N, Choudhary NS, Marannan NK, Ormeci N, Saraf N, Verma N, Nakayama N, Kawada N, Oidov Baatarkhuu, Goyal O, Yokosuka O, Rao PN, Angeli P, Parikh P, Kamath PS, Thuluvath PJ, Lingohr P, Ranjan P, Bhangui P, Rathi P, Sakhuja P, Puri P, Ning Q, Dhiman RK, Kumar R, Vijayaraghavan R, Khanna R, Maiwall R, Mohanka R, Moreau R, Gani RA, Loomba R, Mehtani R, Rajaram RB, Hamid SS, Palnitkar S, Lal S, Biswas S, Chirapongsathorn S, Agarwal S, Sachdeva S, Saigal S, Kumar SE, Violeta S, Singh SP, Mochida S, Mukewar S, Alam S, Lim SG, Alam S, Shalimar, Venishetty S, Sundaram SS, Shetty S, Bhatia S, Singh SA, Kottilil S, Strasser S, Shasthry SM, Maung ST, Tan SS, Treeprasertsuk S, Asthana S, Manekeller S, Gupta S, Acharya SK, K C S, Maharshi S, Asrani S, Dadhich S, Taneja S, Giri S, Singh S, Chen T, Gupta T, Kanda T, Tanwandee T, Piratvishuth T, Spengler U, Prasad VGM, Midha V, Rakhmetova V, Arroyo V, Sood V, Br VK, Wong VW, Pamecha V, Singh V, Dayal VM, Saraswat VA, Kim W, Jafri W, Gu W, Jun WY, Qi X, Chawla YK, Kim YJ, Shi Y, Abbas Z, Kumar G, Shiina S, Wei L, Omata M, Sarin SK; APASL-ACLF Research Consortium (AARC) for APASL-ACLF working party. Acute-on-chronic liver failure (ACLF): the 'Kyoto Consensus'-steps from Asia. Hepatol Int. 2025 Feb;19(1):1-69. doi: 10.1007/s12072-024-10773-4. Epub 2025 Feb 17. PMID: 39961976; PMCID: PMC11846769.

Thomas VV, Kumar SE, Alexander V, Nadaraj A, Vijayalekshmi B, Prabhu S, Kumar S, Murugabharathy K, Thomas SM, Hansdak S, Carey R, Iyyadurai R, Pichamuthu K, Abhilash KPP, Varghese GM, Nair S, Goel A, Jeyaseelan L, Zachariah U, Zachariah A, Eapen CE. Plasma Von Willebrand Factor Levels Predict Survival in COVID-19 Patients Across the Entire Spectrum of Disease Severity. Indian J Hematol Blood Transfus. 2021 Jun 20:1-8. doi: 10.1007/s12288-021-01459-0. Epub ahead of print. PMID: 34177141; PMCID: PMC8214842.

Santhosh E. Kumar, Ashish Goel, Uday Zachariah, Sukesh C. Nair, Vinoi G. David, Santosh Varughese, Prashanth B. Gandhi, Amit Barpha, Anand Sharma, Balakrishnan Vijayalekshmi, Kunissery A. Balasubramanian, Elwyn Elias, Chundamannil Eapen Eapen, Low Volume Plasma Exchange and Low Dose Steroid Improve Survival in Patients With Alcohol-Related Acute on Chronic Liver Failure and Severe Alcoholic Hepatitis – Preliminary Experience, Journal of Clinical and Experimental Hepatology, 2021, ISSN 0973-6883, https://doi.org/10.1016/j.jceh.2021.07.010. (https://www.sciencedirect.com/science/article/pii/S0973688321001778) Abstract: Background Alcohol-related acute on chronic liver failure (A-ACLF) patients have high short-term mortality and are poor candidates for steroid therapy. Plasma exchange (PLEX) improves survival in ACLF patients. We analyzed our experience with low volume PLEX (50% of plasma volume exchanged per session) and low dose steroids to treat A-ACLF patients. Methods We retrospectively compared the efficacy of low volume PLEX and low-dose steroids with standard medical treatment (SMT) in A-ACLF patients treated at our center between November 2017 to June 2019. The primary study outcome was one-year survival. Results Twenty-one A-ACLF patients in PLEX group [age 40 (29–56) years, median (range); MELD score 31 (29–46)] and 29 A-ACLF patients in SMT group [age 41.5 (28–63) years, MELD score 37 (21–48)] were studied. All 50 study patients had severe alcoholic hepatitis [mDF 84.7 (50–389)]. PLEX group patients had 3 (1–7) PLEX sessions with 1.5 (1.4–1.6) liters of plasma exchanged per session and oral Prednisolone 20 mg daily, tapered over 1 month. Kaplan Meier analysis showed better survival over 1 year in the PLEX group compared to the SMT group (P = 0.03). There was renal dysfunction in 10 patients in the PLEX group, which normalized in six patients after PLEX. Conclusion

Kumar SE, Jaleel R, Varghese T, Praharaj I, Benny S, Chowdhury SD, Thomas R, Simon E, Joseph AJ, Dutta AK. Fecal calgranulin as a potential screening tool to differentiate inflammatory bowel disease from irritable bowel syndrome. Indian J Gastroenterol. 2024 Jan 23. doi: 10.1007/s12664-024-01525-1. Epub ahead of print. PMID: 38261246.

Singh KA, Anandan S, Sharma A, Kumar SE, Solaimalai D, Veeraraghavan B, Goel A, Eapen CE, Zachariah UG. High Mortality With Non-O1/Non-O139 Vibrio cholera Bacteraemia in Patients With Cirrhosis. J Clin Exp Hepatol. 2024 May-Jun;14(3):101346. doi: 10.1016/j.jceh.2024.101346. Epub 2024 Jan 17. PMID: 38371607; PMCID: PMC10869911.

Choudhury A, Kulkarni AV, Arora V, Soin AS, Dokmeci AK, Chowdhury A, Koshy A, Duseja A, Kumar A, Mishra AK, Patwa AK, Sood A, Roy A, Shukla A, Chan A, Krag A, Mukund A, Mandot A, Goel A, Butt AS, Sahney A, Shrestha A, Cárdenas A, Di Giorgio A, Arora A, Anand AC, Dhawan A, Jindal A, Saraya A, Srivastava A, Kumar A, Kaewdech A, Pande A, Rastogi A, Valsan A, Goel A, Kumar A, Singal AK, Tanaka A, Coilly A, Singh A, Meena BL, Jagadisan B, Sharma BC, Lal BB, Eapen CE, Yaghi C, Kedarisetty CK, Kim CW, Panackel C, Yu C, Kalal CR, Bihari C, Huang CH, Vasishtha C, Jansen C, Strassburg C, Lin CY, Karvellas CJ, Lesmana CRA, Philips CA, Shawcross D, Kapoor D, Agrawal D, Payawal DA, Praharaj DL, Jothimani D, Song DS, Kim DJ, Kim DS, Zhongping D, Karim F, Durand F, Shiha GE, D'Amico G, Lau GK, Pati GK, Narro GEC, Lee GH, Adali G, Dhakal GP, Szabo G, Lin HC, Li H, Nair HK, Devarbhavi H, Tevethia H, Ghazinian H, Ilango H, Yu HL, Hasan I, Fernandez J, George J, Behari J, Fung J, Bajaj J, Benjamin J, Lai JC, Jia J, Hu JH, Chen JJ, Hou JL, Yang JM, Chang J, Trebicka J, Kalf JC, Sollano JD, Varghese J, Arab JP, Li J, Reddy KR, Raja K, Panda K, Kajal K, Kumar K, Madan K, Kalista KF, Thanapirom K, Win KM, Suk KT, Devadas K, Lesmana LA, Kamani L, Premkumar M, Niriella MA, Al Mahtab M, Yuen MF, Sayed MH, Alla M, Wadhawan M, Sharma MK, Sahu M, Prasad M, Muthiah MD, Schulz M, Bajpai M, Reddy MS, Praktiknjo M, Yu ML, Prasad M, Sharma M, Elbasiony M, Eslam M, Azam MG, Rela M, Desai MS, Vij M, Mahmud N, Choudhary NS, Marannan NK, Ormeci N, Saraf N, Verma N, Nakayama N, Kawada N, Oidov Baatarkhuu, Goyal O, Yokosuka O, Rao PN, Angeli P, Parikh P, Kamath PS, Thuluvath PJ, Lingohr P, Ranjan P, Bhangui P, Rathi P, Sakhuja P, Puri P, Ning Q, Dhiman RK, Kumar R, Vijayaraghavan R, Khanna R, Maiwall R, Mohanka R, Moreau R, Gani RA, Loomba R, Mehtani R, Rajaram RB, Hamid SS, Palnitkar S, Lal S, Biswas S, Chirapongsathorn S, Agarwal S, Sachdeva S, Saigal S, Kumar SE, Violeta S, Singh SP, Mochida S, Mukewar S, Alam S, Lim SG, Alam S, Shalimar, Venishetty S, Sundaram SS, Shetty S, Bhatia S, Singh SA, Kottilil S, Strasser S, Shasthry SM, Maung ST, Tan SS, Treeprasertsuk S, Asthana S, Manekeller S, Gupta S, Acharya SK, K C S, Maharshi S, Asrani S, Dadhich S, Taneja S, Giri S, Singh S, Chen T, Gupta T, Kanda T, Tanwandee T, Piratvishuth T, Spengler U, Prasad VGM, Midha V, Rakhmetova V, Arroyo V, Sood V, Br VK, Wong VW, Pamecha V, Singh V, Dayal VM, Saraswat VA, Kim W, Jafri W, Gu W, Jun WY, Qi X, Chawla YK, Kim YJ, Shi Y, Abbas Z, Kumar G, Shiina S, Wei L, Omata M, Sarin SK; APASL-ACLF Research Consortium (AARC) for APASL-ACLF working party. Acute-on-chronic liver failure (ACLF): the 'Kyoto Consensus'-steps from Asia. Hepatol Int. 2025 Feb;19(1):1-69. doi: 10.1007/s12072-024-10773-4. Epub 2025 Feb 17. PMID: 39961976; PMCID: PMC11846769.